Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases. The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which have completed the Phase III clinical trials for the eradication of Helicobacter pylori infection. The company has the rights in the United States, Europe, and Canada for P-CAB. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Period	Debt/Equity
2019-12-31	0.13
2020-12-31	0.52
2021-12-31	1.63
2022-12-31	-3.20
2023-12-31	-6.69
2024-12-31	-2.49

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PHAT	$12.64	+0.00%	1.67M
3
4
5

Phathom Pharmaceuticals Inc. (PHAT) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Phathom Pharmaceuticals Inc. Data in Excel

More PHAT Financial Data